- Home
- BMRN vs JHX Comparison
BMRN vs JHX Comparison
Compare BMRN & JHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | JHX |
|---|---|---|
| Founded | 1996 | 1888 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 11.8B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | BMRN | JHX |
|---|---|---|
| Price | $53.40 | $19.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $88.42 | $28.60 |
| AVG Volume (30 Days) | 3.0M | ★ 6.6M |
| Earning Date | 10-27-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.53 | N/A |
| EPS | ★ 2.68 | 0.40 |
| Revenue | $3,094,001,000.00 | ★ $4,116,899,999.00 |
| Revenue This Year | $13.39 | $24.54 |
| Revenue Next Year | $7.57 | $15.32 |
| P/E Ratio | ★ $19.92 | $59.44 |
| Revenue Growth | ★ 12.39 | 4.60 |
| 52 Week Low | $50.76 | $16.46 |
| 52 Week High | $73.51 | $29.83 |
Technical Indicators
Market Signals| Indicator | BMRN | JHX |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 58.78 |
| Support Level | $53.03 | $19.14 |
| Resistance Level | $54.66 | $19.90 |
| Average True Range (ATR) | 1.45 | 0.57 |
| MACD | -0.11 | 0.31 |
| Stochastic Oscillator | 31.61 | 97.74 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.